A Phase 3 interventional study of Adapalene/Benzoyl Peroxide in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.
Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 4th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2004.
This study's enrollment of 452 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 215 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 12th largest by enrollment of the 46 interventional ones that give a count, is the only one that started in 2004, is one of 20 in phase 3, and was the 5th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing adapalene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multi-center, open-label, non-comparative study that evaluated the long-term safety and efficacy profile of Adapalene/Benzoyl Peroxide Gel.
Subjects were evaluated at Baseline, Weeks 1 and 2, and Months 1, 2, 4, 6, 8, 10, and 12.
Safety was evaluated by spontaneous reports of Adverse Events (AEs), the Local Tolerability Assessment (Erythema, Scaling, Dryness, and Stinging/Burning), routine laboratory testing (hematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations. Efficacy was evaluated by analysis of Percent Change from Baseline in Inflammatory, Noninflammatory, and Total Lesion Counts, and by the Subject's Assessment of Acne.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 percent (%) (W/W) gel topically to the face and trunk area once daily in the evening.
Drug: Adapalene/Benzoyl Peroxide
Drug pages: Adapalene · Benzoyl Peroxide
Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF
Percent change in inflammatory, noninflammatory and total lesions at Month 12 was measured from baseline lesions. The noninflammatory lesion count was the sum of open comedones (a mass of sebaceous material that is impacted behind an open follicular orifice (blackhead) and closed comedones (a mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead). The inflammatory lesion count was the sum of papules (a small, solid elevation less than 1.0 cm in diameter) and pustules (a small, circumscribed elevation of the skin that contains yellow-white exudate). The total lesion count was the sum of inflammatory and noninflammatory lesions. Missing adapalene and benzoyl peroxide data were imputed using last observation carried forward (LOCF).
Time frame: Baseline, Month 12 LOCF
Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 6
Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.
Time frame: At Month 6
Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 12
Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.
Time frame: At Month 12
Number of Participants With Local Tolerability Assessment For Erythema
Local tolerability assessment for erythema (abnormal redness of the skin) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no erythema), mild (1- slight pinkness present), moderate (2- definite redness, easily recognized), severe (3- intense redness). The worst severity scores were generally mild or moderate, and rarely severe.
Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Number of Participants With Local Tolerability Assessment For Scaling
Local tolerability assessment for scaling (abnormal shedding of the stratum corneum) was graded on a "0" (none) to "3" (severe) scale as follow; none (0- no Scaling), mild (1- barely perceptible shedding, noticeable only on light scratching or rubbing), moderate (2- obvious but not profuse shedding), severe (3- heavy scale production).
Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Number of Participants With Local Tolerability Assessment For Dryness
Local tolerability assessment for dryness (brittle and/or tight sensation) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no dryness), mild (1- slight but definite roughness), moderate (2 -moderate roughness), severe (3- marked roughness).
Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Number of Participants With Local Tolerability Assessment For Stinging/Burning
Local tolerability assessment for stinging/burning \[prickling pain sensation immediately after (within 5 minutes of) dosing\] was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no stinging/ burning), mild (1- slight warm, tingling/stinging sensation; not really bothersome), moderate (2- definite warm, tingling/stinging sensation that is somewhat), severe (3- hot, tingling/stinging sensation that has caused definite discomfort).
Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Baseline up to Month 14
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Clinical laboratory parameters included hematology, blood chemistry, urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported.
Time frame: Baseline up to Month 14
A total of 452 participants were enrolled at 28 study centers in the United States from 17 February 2004 to 23 May 2005.
| Milestone | Adapalene/Benzoyl Peroxide |
|---|---|
| Started | 452 |
| Completed | 327 |
| Not completed | 125 |
| Withdrew: Adverse event | 9 |
| Withdrew: Withdrawal by subject | 70 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Lost to follow-up | 42 |
| Withdrew: Pregnancy | 2 |
Percent change in inflammatory, noninflammatory and total lesions at Month 12 was measured from baseline lesions. The noninflammatory lesion count was the sum of open comedones (a mass of sebaceous material that is impacted behind an open follicular orifice (blackhead) and closed comedones (a mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead). The inflammatory lesion count was the sum of papules (a small, solid elevation less than 1.0 cm in diameter) and pustules (a small, circumscribed elevation of the skin that contains yellow-white exudate). The total lesion count was the sum of inflammatory and noninflammatory lesions. Missing adapalene and benzoyl peroxide data were imputed using last observation carried forward (LOCF).
| percent change | Adapalene/Benzoyl Peroxide |
|---|---|
| Inflammatory Lesion Counts | -59.70 ± 34.268 |
| Noninflammatory Lesion Counts | -58.80 ± 33.206 |
| Total Lesion Counts | -58.85 ± 29.273 |
Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| 0=Complete Improvement | 17 |
| 1=Marked Improvement | 149 |
| 2=Moderate Improvement | 147 |
| 3=Minimal Improvement | 31 |
| 4=No Change | 11 |
| 5=Worse | 4 |
Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| 0=Complete Improvement | 40 |
| 1=Marked Improvement | 164 |
| 2=Moderate Improvement | 77 |
| 3=Minimal Improvement | 37 |
| 4=No Change | 6 |
| 5=Worse | 3 |
Local tolerability assessment for erythema (abnormal redness of the skin) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no erythema), mild (1- slight pinkness present), moderate (2- definite redness, easily recognized), severe (3- intense redness). The worst severity scores were generally mild or moderate, and rarely severe.
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Baseline — 0 = None | 348 |
| Baseline — 1 = Mild | 94 |
| Baseline — 2=Moderate | 10 |
| Baseline — 3=Severe | 0 |
| Week 1 — 0 = None | 233 |
| Week 1 — 1 = Mild | 157 |
| Week 1 — 2=Moderate | 32 |
| Week 1 — 3=Severe | 1 |
| Week 2 — 0 = None | 277 |
| Week 2 — 1 = Mild | 133 |
| Week 2 — 2=Moderate | 17 |
| Week 2 — 3=Severe | 2 |
| Month 1 — 0 = None | 292 |
| Month 1 — 1 = Mild | 105 |
| Month 1 — 2=Moderate | 18 |
| Month 1 — 3=Severe | 0 |
| Month 2 — 0 = None | 320 |
| Month 2 — 1 = Mild | 90 |
| Month 2 — 2=Moderate | 16 |
| Month 2 — 3=Severe | 0 |
| Month 4 — 0 = None | 334 |
| Month 4 — 1 = Mild | 48 |
| Month 4 — 2=Moderate | 7 |
| Month 4 — 3=Severe | 0 |
| Month 6 — 0 = None | 296 |
| Month 6 — 1 = Mild | 59 |
| Month 6 — 2=Moderate | 6 |
| Month 6 — 3=Severe | 0 |
| Month 8 — 0 = None | 276 |
| Month 8 — 1 = Mild | 57 |
| Month 8 — 2=Moderate | 8 |
| Month 8 — 3=Severe | 0 |
| Month 10 — 0 = None | 270 |
| Month 10 — 1 = Mild | 56 |
| Month 10 — 2=Moderate | 3 |
| Month 10 — 3=Severe | 0 |
| Month 12 — 0 = None | 284 |
| Month 12 — 1 = Mild | 39 |
| Month 12 — 2=Moderate | 4 |
| Month 12 — 3=Severe | 0 |
Local tolerability assessment for scaling (abnormal shedding of the stratum corneum) was graded on a "0" (none) to "3" (severe) scale as follow; none (0- no Scaling), mild (1- barely perceptible shedding, noticeable only on light scratching or rubbing), moderate (2- obvious but not profuse shedding), severe (3- heavy scale production).
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Baseline — 0=None | 410 |
| Baseline — 1=Mild | 41 |
| Baseline — 2=Moderate | 1 |
| Baseline — 3=Severe | 0 |
| Week 1 — 0=None | 228 |
| Week 1 — 1=Mild | 164 |
| Week 1 — 2=Moderate | 30 |
| Week 1 — 3=Severe | 1 |
| Week 2 — 0=None | 284 |
| Week 2 — 1=Mild | 130 |
| Week 2 — 2=Moderate | 14 |
| Week 2 — 3=Severe | 1 |
| Month 1 — 0=None | 312 |
| Month 1 — 1=Mild | 93 |
| Month 1 — 2=Moderate | 10 |
| Month 1 — 3=Severe | 0 |
| Month 2 — 0=None | 338 |
| Month 2 — 1=Mild | 84 |
| Month 2 — 2=Moderate | 4 |
| Month 2 — 3=Severe | 0 |
| Month 4 — 0=None | 351 |
| Month 4 — 1=Mild | 38 |
| Month 4 — 2=Moderate | 0 |
| Month 4 — 3=Severe | 0 |
| Month 6 — 0=None | 330 |
| Month 6 — 1=Mild | 28 |
| Month 6 — 2=Moderate | 3 |
| Month 6 — 3=Severe | 0 |
| Month 8 — 0=None | 301 |
| Month 8 — 1=Mild | 38 |
| Month 8 — 2=Moderate | 2 |
| Month 8 — 3=Severe | 0 |
| Month 10 — 0=None | 294 |
| Month 10 — 1=Mild | 33 |
| Month 10 — 2=Moderate | 2 |
| Month 10 — 3=Severe | 0 |
| Month 12 — 0=None | 308 |
| Month 12 — 1=Mild | 19 |
| Month 12 — 2=Moderate | 0 |
| Month 12 — 3=Severe | 0 |
Local tolerability assessment for dryness (brittle and/or tight sensation) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no dryness), mild (1- slight but definite roughness), moderate (2 -moderate roughness), severe (3- marked roughness).
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Baseline — 0=None | 385 |
| Baseline — 1=Mild | 65 |
| Baseline — 2=Moderate | 2 |
| Baseline — 3=Severe | 0 |
| Week 1 — 0=None | 195 |
| Week 1 — 1=Mild | 190 |
| Week 1 — 2=Moderate | 35 |
| Week 1 — 3=Severe | 3 |
| Week 2 — 0=None | 264 |
| Week 2 — 1=Mild | 152 |
| Week 2 — 2=Moderate | 12 |
| Week 2 — 3=Severe | 1 |
| Month 1 — 0=None | 281 |
| Month 1 — 1=Mild | 121 |
| Month 1 — 2=Moderate | 12 |
| Month 1 — 3=Severe | 1 |
| Month 2 — 0=None | 311 |
| Month 2 — 1=Mild | 109 |
| Month 2 — 2=Moderate | 6 |
| Month 2 — 3=Severe | 0 |
| Month 4 — 0=None | 337 |
| Month 4 — 1=Mild | 52 |
| Month 4 — 2=Moderate | 0 |
| Month 4 — 3=Severe | 0 |
| Month 6 — 0=None | 320 |
| Month 6 — 1=Mild | 37 |
| Month 6 — 2=Moderate | 4 |
| Month 6 — 3=Severe | 0 |
| Month 8 — 0=None | 281 |
| Month 8 — 1=Mild | 58 |
| Month 8 — 2=Moderate | 2 |
| Month 8 — 3=Severe | 0 |
| Month 10 — 0=None | 278 |
| Month 10 — 1=Mild | 48 |
| Month 10 — 2=Moderate | 3 |
| Month 10 — 3=Severe | 0 |
| Month 12 — 0=None | 291 |
| Month 12 — 1=Mild | 36 |
| Month 12 — 2=Moderate | 0 |
| Month 12 — 3=Severe | 0 |
Local tolerability assessment for stinging/burning \[prickling pain sensation immediately after (within 5 minutes of) dosing\] was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no stinging/ burning), mild (1- slight warm, tingling/stinging sensation; not really bothersome), moderate (2- definite warm, tingling/stinging sensation that is somewhat), severe (3- hot, tingling/stinging sensation that has caused definite discomfort).
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Baseline — 0=None | 440 |
| Baseline — 1=Mild | 10 |
| Baseline — 2=Moderate | 2 |
| Baseline — 3=Severe | 0 |
| Week 1 — 0=None | 201 |
| Week 1 — 1=Mild | 154 |
| Week 1 — 2=Moderate | 63 |
| Week 1 — 3=Severe | 5 |
| Week 2 — 0=None | 319 |
| Week 2 — 1=Mild | 84 |
| Week 2 — 2=Moderate | 21 |
| Week 2 — 3=Severe | 5 |
| Month 1 — 0=None | 331 |
| Month 1 — 1=Mild | 66 |
| Month 1 — 2=Moderate | 14 |
| Month 1 — 3=Severe | 4 |
| Month 2 — 0=None | 373 |
| Month 2 — 1=Mild | 42 |
| Month 2 — 2=Moderate | 10 |
| Month 2 — 3=Severe | 1 |
| Month 4 — 0=None | 364 |
| Month 4 — 1=Mild | 23 |
| Month 4 — 2=Moderate | 2 |
| Month 4 — 3=Severe | 0 |
| Month 6 — 0=None | 337 |
| Month 6 — 1=Mild | 20 |
| Month 6 — 2=Moderate | 4 |
| Month 6 — 3=Severe | 0 |
| Month 8 — 0=None | 312 |
| Month 8 — 1=Mild | 23 |
| Month 8 — 2=Moderate | 5 |
| Month 8 — 3=Severe | 1 |
| Month 10 — 0=None | 303 |
| Month 10 — 1=Mild | 22 |
| Month 10 — 2=Moderate | 4 |
| Month 10 — 3=Severe | 0 |
| Month 12 — 0=None | 306 |
| Month 12 — 1=Mild | 19 |
| Month 12 — 2=Moderate | 1 |
| Month 12 — 3=Severe | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Participants (N) With At least one AE | 288 |
| Participants (N) With At Least one SAE | 5 |
Clinical laboratory parameters included hematology, blood chemistry, urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported.
| Participants | Adapalene/Benzoyl Peroxide |
|---|---|
| Hematology | 0 |
| Blood Chemistry | 0 |
| Urine Analysis | 0 |
Collected over Baseline up to 14 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adapalene/Benzoyl Peroxide | 0/452 (0%) | 5/452 (1.1%) | 288/452 (63.7%) |
| Event | Adapalene/Benzoyl Peroxide |
|---|---|
| Major DepressionPsychiatric disorders | 1/452 |
| Bipolar DisorderPsychiatric disorders | 1/452 |
| Staphylococcal InfectionInfections and infestations | 1/452 |
| Clavicle FractureInjury, poisoning and procedural complications | 1/452 |
| SyncopeNervous system disorders | 1/452 |
| Drug AbuserSocial circumstances | 1/452 |
| Event | Adapalene/Benzoyl Peroxide |
|---|---|
| Dry SkinSkin and subcutaneous tissue disorders | 80/452 |
| Application Site BurningGeneral disorders | 64/452 |
| NasopharyngitisInfections and infestations | 30/452 |
| Upper Respiratory Tract InfectionInfections and infestations | 26/452 |
| ErythemaSkin and subcutaneous tissue disorders | 25/452 |
| Skin DesquamationSkin and subcutaneous tissue disorders | 23/452 |
| SunburnInjury, poisoning and procedural complications | 21/452 |
| HeadacheNervous system disorders | 21/452 |
| InfluenzaInfections and infestations | 18/452 |
| Application Site IrritationGeneral disorders | 18/452 |
The intent-to-treat (ITT) population included all participants who were enrolled and to whom medication was dispensed.
| Age, Continuous(years) | Adapalene/Benzoyl Peroxide |
|---|---|
| Mean | 18.3 ± 6.62 |
| Sex: Female, Male(Participants) | Adapalene/Benzoyl Peroxide |
|---|---|
| Female | 230 |
| Male | 222 |
| Race/Ethnicity, Customized(Participants) | Adapalene/Benzoyl Peroxide |
|---|---|
| Race — Caucasian | 345 |
| Race — Black | 53 |
| Race — Asian | 10 |
| Race — Hispanic | 31 |
| Race — Other | 13 |
Ran from Feb 2004 to primary completion in May 2005, 15 months.
Results were first posted in Jul 2023, 18 years 1 month after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 15 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adapalene · Benzoyl Peroxide